Combined use of Fc gamma RIIb (CD32B) and CD20-specific antibodies
US10525129B2 · kind B2 · utility
1Cited by
9References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 19, 2011 |
| Grant date | Jan 7, 2020 |
| Priority date | — |
| Expiry date | Nov 6, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/507
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.